Akebia Therapeutics, Inc. (AKBA)
NASDAQ: AKBA · Real-Time Price · USD
1.910
-0.020 (-1.04%)
Mar 28, 2025, 4:00 PM EDT - Market closed
Akebia Therapeutics Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Akebia Therapeutics stock have an average target of 6.75, with a low estimate of 6.00 and a high estimate of 7.50. The average target predicts an increase of 253.40% from the current stock price of 1.91.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Akebia Therapeutics stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 1 | 1 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Maintains $4 → $6 | Buy | Maintains | $4 → $6 | +214.14% | Mar 14, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7.5 | Strong Buy | Reiterates | $7.5 | +292.67% | Mar 14, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7.5 | Strong Buy | Reiterates | $7.5 | +292.67% | Jan 23, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7.5 | Strong Buy | Reiterates | $7.5 | +292.67% | Jan 14, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7.5 | Strong Buy | Reiterates | $7.5 | +292.67% | Oct 23, 2024 |
Financial Forecast
Revenue This Year
183.81M
from 160.18M
Increased by 14.75%
Revenue Next Year
250.34M
from 183.81M
Increased by 36.19%
EPS This Year
-0.22
from -0.33
EPS Next Year
0.05
from -0.22
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 206.0M | 261.2M | 462.2M | ||
| Avg | 183.8M | 250.3M | 356.1M | ||
| Low | 164.1M | 237.2M | 252.9M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 28.6% | 42.1% | 84.6% | ||
| Avg | 14.8% | 36.2% | 42.2% | ||
| Low | 2.5% | 29.1% | 1.0% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.04 | 0.40 | 0.34 | ||
| Avg | -0.22 | 0.05 | 0.28 | ||
| Low | -0.35 | -0.27 | 0.23 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 558.8% | ||
| Avg | - | - | 450.0% | ||
| Low | - | - | 342.0% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.